Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 1986;111(3):182-6.
doi: 10.1007/BF00389231.

In vivo augmentation of the cytotoxicity of spleen lymphocytes against syngeneic B-16 melanoma cells and the suppression of the artificial metastases in C57BL/6 mice by subcutaneous multiple injections of high dose human recombinant interleukin-2 (rIL-2)

N Saijo, A Ozaki, H Nakano, M Sakurai, H Takahashi, Y Sasaki, A Hoshi

In vivo augmentation of the cytotoxicity of spleen lymphocytes against syngeneic B-16 melanoma cells and the suppression of the artificial metastases in C57BL/6 mice by subcutaneous multiple injections of high dose human recombinant interleukin-2 (rIL-2)

N Saijo et al. J Cancer Res Clin Oncol. 1986.

Abstract

The cytotoxicity of spleen lymphocytes against YAC-1 cells, against syngeneic B-16 and F-10 melanoma cells was augmented not only by incubation of spleen lymphocytes with human recombinant interleukin-2 (rIL-2) in vitro, but also by injecting C57BL/6 mice with high dose rIL-2 for more than 3 consecutive days. In animals injected s.c. with multiple high dose rIL-2, the numbers of tumor nodules in the lung were significantly decreased 21 days after i.v. tumor inoculation. In addition, in these groups of animals no liver metastases were observed although liver metastases were detected in 6/11 control mice.

PubMed Disclaimer

Similar articles

See all similar articles

Cited by

References

    1. Bindon C, Czerniecki M., Ruell P., Edwards A, McCarthy WH, Harris R, Hersey P (1983) Clearance rates and systemic effects of intravenously administered interleukin-2 (IL-2) containing preparations in human subjects. Br J Cancer 47:123–133 - PMC - PubMed
    1. Bubenik J, Indrova M, Perlmann P, Berzins K, March O, Okraml J, Toulcova A (1985) Tumor inhibitory effects of TCGF/IL-2 containing preparations. Cancer Immunol Immunother 19:57–61 - PMC - PubMed
    1. Donohue JH, Rosenberg SA (1983) The fate of interleukin-2 after in vivo administration. J Immunol 130:2203–2208 - PubMed
    1. Donohue LH, Lotze MT, Robb RJ, Rosenstein M, Braziel RM, Jaffe ES, Rosenberg SA (1984) In vivo administration of purified jurkat-derived interleukin-2 in mice. Cancer Res 44:1380–1386 - PubMed
    1. Flomenberg N, Welte K, Mertelsmann R, Kernan N, Ciobanu N, Venuta S, Feldman S, Kruger G, Kirkpatrick D, Dupont B, O'Reilly R (1983) Immunologic effects of interleukin-2 in primary immunodeficiency diseases. J Immunol 130:2644–2649 - PubMed

Publication types

LinkOut - more resources